Phase III: Pimavanserin In Patients With Parkinson's Disease Psychosis
 

ACADIA Pharmaceuticals Initiates Second Phase III Trial With Pimavanserin In Patients With Parkinson's Disease Psychosis

Main Category: Parkinson's Disease
Article Date: 03 Apr 2008 - 1:00 PDT

ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, announced that it has initiated its second Phase III trial designed to evaluate the safety and efficacy of pimavanserin as a treatment for Parkinson's disease psychosis (PDP).

"The start of our second Phase III pivotal trial represents another important step forward toward our goal of providing a first-in-class treatment for patients with PDP," said Uli Hacksell, Ph.D., Chief Executive Officer of ACADIA Pharmaceuticals. "We believe pimavanserin may provide a unique combination of antipsychotic efficacy, motoric tolerability and safety and, therefore, provides the potential for an important advance in therapy for patients suffering from this debilitating disorder."

About Pimavanserin

Pimavanserin tartrate is a novel, potent, and selective 5-HT2A inverse agonist that ACADIA discovered and is developing as a treatment for PDP. ACADIA is currently conducting two Phase III pivotal trials in its program with pimavanserin as a treatment for PDP. ACADIA has also reported positive results from a Phase II trial in its program with pimavanserin as a co-therapy for schizophrenia.

READ more

"Thu Apr 11, 2013 9:43am EDT

(Reuters) - Acadia Pharmaceuticals Inc said data from an initial late-stage trial would be sufficient to file for approval for its experimental antipsychotic drug for Parkinson's disease patients, ...

Parkinson's disease psychosis is a debilitating disorder that develops in up to 60 percent of patients as their Parkinson's disease progresses.

Most current antipsychotic drugs cannot be used in Parkinson's disease patients as they block dopamine in the brain, which is the primary target for Parkinson's therapy, and can lead to a worsening of motor functions in such patients.

Pimavanserin works by selectively blocking certain serotonin receptors in the brain, but has no effect on dopamine..."

http://www.reuters.com/article/2013/...93A0IA20130411

John